

Press Release

Zug, 31 October 2011

New CFO at HBM BioVentures

Mr Erwin Troxler (41) will take over responsibility as Chief Financial Officer of HBM BioVentures Ltd effective 1 November 2011. Mr Troxler has headed up several areas within the Finance Department at HBM Partners since 2005. He was formerly Audit Manager at PricewaterhouseCoopers, serving clients in the financial services industry, before spending a number of years at Julius Baer looking after investment companies in the private equity segment. Erwin Troxler holds a degree of the Lucerne School of Economics and Business Administration (HWV) and is a Swiss Certified Public Accountant.

Mr Joachim Rudolf, CFO of HBM BioVentures since its foundation in 2001, is leaving the Company at his own request to become CFO of Cathay Industrial Biotech, the largest private company in the HBM BioVentures portfolio. The Board of Directors would like to thank Mr Rudolf for his long-standing commitment and for his outstanding work at HBM BioVentures, and wishes him all the best for the future.

For further information, please contact Dr. Andreas Wicki, CEO HBM BioVentures Ltd, tel.: +41 41 768 11 08, andreas.wicki@hmbioventures.com.

Brief profile of HBM BioVentures Ltd

HBM BioVentures invests in the healthcare sector. The Company holds and manages an international portfolio of some twenty five promising companies in the biotechnology/human medicine, medical technology and diagnostics sectors. Many of these companies have their lead products already available on the market, or at an advanced stage of development. The focus of investment is on follow-on financing for existing portfolio companies. These portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM BioVentures an interesting alternative to investing in big pharma and biotech companies. HBM BioVentures has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities.

This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug / Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com